Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This study evaluates navtemadlin as maintenance treatment for patients with advanced or
recurrent endometrial cancer (EC) who have achieved complete response or partial response on
chemotherapy.
The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two
different doses of navtemadlin alongside an observational control arm to determine the Phase
3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose
compared to placebo.